Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070594 | 0.93 | MAPK1 (0.54) | MAPK1ITKROCK2HDAC1HDAC3 | |
| SCHEMBL6071239 | 0.82 | KDM4E (0.47) | ITKROCK2HDAC1HDAC3HDAC6 | |
| SCHEMBL6070823 | 0.81 | HDAC3 (0.42) | MAPK1ROCK2HDAC1HDAC3HPGD | |
| SCHEMBL6071427 | 0.80 | KDM4E (0.54) | HDAC1HDAC3KDM4EALDH1A1HPGD | |
| SCHEMBL6071757 | 0.78 | ROCK2 (0.43) | MAPK1ITKROCK2MAPTKDM4E | |
| SCHEMBL6071257 | 0.78 | ROCK2 (0.39) | PARP1ITKROCK2HDAC1HDAC3 | |
| SCHEMBL6070463 | 0.78 | IMPDH2 (0.54) | MAPK1ITKROCK2IMPDH2MAPT | |
| SCHEMBL6071299 | 0.78 | ROCK2 (0.49) | MAPK1PARP1ROCK2IMPDH2 | |
| SCHEMBL6070896 | 0.77 | MAPT (0.54) | MAPK1ROCK2MAPTKDM4EALDH1A1 | |
| SCHEMBL6075381 | 0.76 | NHERF1 (0.42) | ROCK2HDAC1HDAC3HDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | claimed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | MAPK1 127/4885PARP1 840/4885ITK 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.